Stock Market Reviews

LYEL (Lyell Immunopharma, Inc.) News

Get the latest news, insights, and market updates on LYEL (Lyell Immunopharma, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
  PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lyell’s next-generation, dual-targeting CD19/CD20 CAR T-cell therapy designed to deliver improved complete response rates and longer duration of responses over currently approved CD19 CAR T-cell therapiesSteering Committee of distinguished lymphoma expe
  Sep 3, 2025 - $LYEL
• Lyell Immunopharma Announces Participation in September Investor Conferences
  SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8th at 9:15 am Eastern TimeH.C. Wainwright 27th
  Sep 2, 2025 - $LYEL
• Lyell Immunopharma: Q2 Earnings Snapshot
  SOUTH SAN FRANCISCO, Calif. AP) — Lyell Immunopharma Inc. LYEL) on Tuesday reported a loss of $42.7 million in its second quarter.
  Aug 12, 2025 - $LYEL
• Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
  Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in the third‑ or later-line (3L+) setting; remain on track to initiate a pivotal trial in the second-line (2L) setting by early 2026Entered into a securities purchase agreement for a private placement for gross proc
  Aug 12, 2025 - $LYEL
• Update: Lyell Immunopharma Shares Rise on Plan to Raise Up to $100 Million in Private Placement
  (Updates with the latest stock movement in the first paragraph and headline.) Lyell Immunopharma
  Jul 25, 2025 - $LYEL
• Lyell Immunopharma to Raise $100 Million in Private Placement; Shares Rise Pre-Bell
  Lyell Immunopharma (LYEL) said Friday it has entered into a securities purchase agreement with certa
  Jul 25, 2025 - $LYEL
• Lyell Immunopharma Announces up to $100 Million Equity Private Placement
  SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximately $100 million. The initial closing of approximately $50 million of common stock at a price of $13.32
  Jul 25, 2025 - $LYEL
• Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
  SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright “HCW@Home” Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET. The discussion will highlight the positive new clinical data recently presented in an oral session at the Interna
  Jun 23, 2025 - $LYEL
• Lyell reports new clinical data from trial of large B-cell lymphoma therapy
  In the study, subjects treated in the 3L+ setting showed an 88% overall response rate.
  Jun 18, 2025 - $LYEL
• Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
  LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with
  Jun 17, 2025 - $LYEL